Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
NEW BRUNSWICK, N.J., December 30, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced new preliminary results from the South African Phase 3b Sisonke study which showed that a homologous (same vaccine) booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S) demonstrated 85 percent effectiveness against COVID-19-related hospitalization. The study, conducted by the South African Medical Research Council (SAMRC), showed that the Johnson & Johnson booster reduced the risk of hospitalization from COVID-19 among healthcare workers in South Africa after Omicron became the dominant variant. During the months studied (mid-November to mid-December) the frequency of Omicron increased from 82 to 98 percent of COVID-19 cases in South Africa as reported by GISAID, an initiative that provides COVID-19 data. A second, separate analysis of the immune response to different vaccine regimens, conducted by Beth Israel Deaconess Medical Center (BIDMC), demonstrated that a heterologous booster (different vaccine) of the Johnson & Johnson COVID-19 vaccine in individuals who initially received the BNT162b2 mRNA vaccine generated a 41-fold increase in neutralizing antibody responses by four weeks following the boost and a 5-fold increase in CD8+ T-cells to Omicron by two weeks. A homologous boost with BNT162b2 generated a 17-fold increase in neutralizing antibodies by four weeks following the boost and a 1.4-fold increase in CD8+ T-cells by two weeks. The ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: African Health | Allergy & Immunology | Biotechnology | Bleeding | Brain | Cancer & Oncology | Cardiology | Cardiovascular | Centers for Disease Control and Prevention (CDC) | Clinical Trials | Coronavirus | COVID-19 | Department of Health | Emergency Medicine | Environmental Health | Eyes | Guillain-Barr Syndrome | Headache | Health Management | Heart | Hospitals | Hypertension | Infectious Diseases | International Medicine & Public Health | Israel Health | Learning | Legislation | Managed Care | Men | Middle East Health | Migraine | Neurology | Neuroscience | Pain | Pandemics | Pharmaceuticals | Pregnancy | Pulmonary Hypertension | Research | Respiratory Medicine | SARS | Science | Skin | South Africa Health | Study | Tinnitus | Universities & Medical Training | USA Health | Vaccines | Virology | WHO